Dr. Stacy Loeb

James McKiernan, MD, is the John K. Lattimer Professor of Urology and CEO of ColumbiaDoctors. He is also Senior Vice Dean for Clinical Affairs for Columbia University Vagelos College of Physicians and Surgeons. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused on urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1,000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues.For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer. Dr. Mckiernan is rated as an Elite provider by MediFind in Prostatectomy. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy.

Howard Scher is an Oncologist in New York, New York. Dr. Scher is rated as a Distinguished provider by MediFind in Prostatectomy. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bone Tumor, Orchiectomy, and Prostatectomy. Dr. Scher is currently accepting new patients.

Lee Richstone, MD is the Chairman of Urology and Director of Urology Services for the Western Region. He is also Director of Laparoscopic and Robotic Surgery at Lenox Hill Hospital and System Vice Chairman for Education for Northwell Health Urology. Dr. Richstone is Professor of Urology at The Hofstra-Northwell School of Medicine. Dr. Richstone completed medical school at the Cornell University Medical College in New York City. There he won early acceptance into Alpha Omega Alpha (AOA), the prestigious national medical honor society. He pursued his urologic training and chief residency at New York Presbyterian (Weill-Cornell) and Memorial Sloan Kettering hospitals. Dr. Richstone completed his fellowship training in urologic laparoscopic and robotic surgery and joined the North Shore Long Island Jewish Health System in 2007 as Director of Laparoscopic and Robotic Surgery. He then served as Chief of Urology for the North Shore University Hospital, then Chief of Urology at the Long Island Jewish Medical Center, before assuming the role of Chairman of Urology at Lenox Hill Hospital in Manhattan. Dr. Richstone is an internationally recognized urologic surgeon who has helped pioneer laparoscopic and robotic surgery for cancer of the prostate, kidney and bladder, as well as for various forms of urinary obstructions. He has over 90 peer-reviewed publications in leading national and international journals including The Journal of Urology, Urology, The British Journal of Urology, The Journal of Endourology, Cancer, and Cell.Dr. Richstone is a robotic surgery specialist having performed well over 1000 operations. This includes surgeries for prostate, kidney and bladder cancer and complex neobladder reconstructions completely robotically. His focus is on preserving urinary continence and sexual function. Dr. Richstone has also pioneered Laparoendoscopic Single Site Surgery (LESS), where entire laparoscopic operations are performed only through the belly button. Dr. Richstone is one of only a few surgeons in the United States to have performed single site partial nephrectomy and prostatectomy.Dr. Richstone is a member of the Society of Urologic Oncology (SUO), the America Urological Association (AUA), and the Endourological Society (EUS). Dr. Richstone is the recipient of numerous honors and awards, including acceptance into Alpha Omega Alpha (AOA), the E. Darracott Vaughan Prize for Excellence in Urology (2000), The Ferdinand C. Valentine Urology Essay Prize (First Place, 2005), The American Urological Association-Ambrose Reed Socioeconomic Essay Contest (First Place, 2005), and the Weill-Cornell Distinguished House Officer Award (2005). Dr. Richstone was awarded the Stryker and Nagamatsu Fellowship (2007), and won first prize at the Endourology Society Fellowship Paper Award the same year. Dr. Richstone won first prize at the AUA Research Foundation for Outstanding Research awarded at the 2010 AUA National Meeting in San Francisco. Dr. Richstone is rated as a Distinguished provider by MediFind in Prostatectomy. His top areas of expertise are Bladder Cancer, Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.